Liquidia (NASDAQ:LQDA) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Liquidia (NASDAQ:LQDA) from a buy rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other analysts have also weighed in on LQDA. Royal Bank Of Canada set a $130.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Needham & Company LLC decreased their target price on shares of Liquidia from $110.00 to $72.00 and set a “buy” rating for the company in a research report on Thursday, October 1st. BTIG Research lowered shares of Liquidia from a “buy” rating to a “neutral” rating in a report on Thursday. Bank of America increased their price target on Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Finally, Oppenheimer set a $75.00 price objective on Liquidia in a research note on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $83.69.

Liquidia Stock Down 3.5%

Liquidia stock opened at $27.64 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The business’s 50-day simple moving average is $70.49 and its two-hundred day simple moving average is $62.14. The company has a market cap of $2.47 billion, a PE ratio of 20.18 and a beta of 0.61. Liquidia has a fifty-two week low of $21.94 and a fifty-two week high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the previous year, the business earned ($0.49) earnings per share. The company’s revenue for the quarter was up 1842.1% compared to the same quarter last year. Equities analysts anticipate that Liquidia will post 2.34 EPS for the current year.

Insider Buying and Selling

In other Liquidia news, Director Stephen Bloch sold 100,000 shares of the company’s stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $89.48, for a total value of $8,948,000.00. Following the completion of the transaction, the director owned 501,477 shares in the company, valued at approximately $44,872,161.96. This represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jason Adair sold 73,631 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $69.09, for a total value of $5,087,165.79. Following the transaction, the insider directly owned 174,606 shares of the company’s stock, valued at approximately $12,063,528.54. The trade was a 29.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 522,519 shares of company stock valued at $40,040,514 in the last ninety days. Company insiders own 25.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Bank of America Corp DE raised its holdings in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after buying an additional 360,372 shares during the period. Eversept Partners LP raised its stake in shares of Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after acquiring an additional 167,949 shares in the last quarter. Pale Fire Capital SE boosted its holdings in Liquidia by 2.4% in the first quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after purchasing an additional 8,985 shares during the period. Bank of New York Mellon Corp acquired a new position in Liquidia during the 2nd quarter worth $29,694,000. Finally, Seven Fleet Capital Management LP grew its stake in Liquidia by 25.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after purchasing an additional 51,727 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).